Loading
A phase 3 trial of Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide and Tocilizumab in non-Hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting.
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma is a phase 3 interventional study registered as NCT06084936 by Hoffmann-La Roche, with 182 participants planned, started 2023-10-22 and due to reach its primary completion in 2027-08-31. Interventions recorded: Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide and Tocilizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tocilizumab, Glofitamab, Flatiron Health (Roche), Rituximab and the tag pipeline.
Shares Tocilizumab, Glofitamab, Flatiron Health (Roche), Obinutuzumab and the tag pipeline.
Shares Glofitamab, Flatiron Health (Roche), Obinutuzumab, T-cell engagers (bispecific) and the tag pipeline.
Shares Glofitamab, Obinutuzumab, Mantle cell lymphoma and the tag pipeline.
Shares Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Bendamustine, Obinutuzumab, Rituximab and the tag pipeline.
Shares Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/